Novocure to Participate in Upcoming Investor Conferences 2022/08/31 12:00:00 Wallstreet:Online
Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences. William Doyle, Executive Chairman, and Ashley Cordova, Chief Financial Officer, will participate in the 2022 Wells Fargo Healthcare Conference on September 7, 2022. Mr. Doyle and Ms. Cordova will take part in a fireside chat at 4:20 p.m. EDT, as well as one-on-one meetings with investors
Why I Own Novocure Stock (NVCR) 2022/08/22 14:15:00 The Motley Fool
Motley Fool contributor Brian Orelli shares why he loves this stock
NovoCure Earnings Perspective: Return On Capital Employed 2022/08/04 14:23:56 Benzinga
NovoCure (NASDAQ: NVCR ) brought in sales totaling $140.87 million during Q2 according to data provided by Benzinga Pro . However, earnings decreased 416.63%, resulting in a loss of $24.01 million. In Q1, NovoCure brought in $137.55 million in sales but lost $4.65 million in earnings. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and … Full story available on Benzinga.com
NovoCure Stock: Valuations Are Unattractive Despite Good Q2 2022/07/29 17:09:34 Seeking Alpha
NovoCure printed another successful quarter, but came in behind consensus below the bottom line. See why we are bullish on NVCR stock for long-term.
NovoCure Ltd. PT Lowered to $105 at Truist Securities 2022/07/29 12:11:17 Investing.com
NovoCure Limited (NASDAQ:NVCR) Is 22.21% Above Its 52-Week Low, But How Long Can It Continue? 2022/04/30 12:00:00 Marketing Sentinel
In last trading session, NovoCure Limited (NASDAQ:NVCR) saw 0.65 million shares changing hands with its beta currently measuring 0.85. Company’s recent per share price level of $76.58 trading at -$0.6 or -0.78% at ring of the bell on the day assigns it a market valuation of $8.58B. That closing price of NVCR’s stock is at … NovoCure Limited (NASDAQ:NVCR) Is 22.21% Above Its 52-Week Low, But How Long Can It Continue? Read More »
Novocure (NVCR) Q1 2022 Earnings Call Transcript 2022/04/28 17:30:35 The Motley Fool
NVCR earnings call for the period ending March 31, 2022.
NovoCure Limited''s (NVCR) Management on Q1 2022 Results - Earnings Call Transcript 2022/04/28 16:30:26 Seeking Alpha
NovoCure Limited (NASDAQ:NASDAQ:NVCR) Q1 2022 Earnings Conference Call April 28, 2022 8:00 AM ET Company Participants Ingrid Goldberg – Investor Relations Bill Doyle – Executive Chairman…
NovoCure: Q1 Earnings Insights 2022/04/28 13:54:48 Benzinga
NovoCure (NASDAQ: NVCR ) reported its Q1 earnings results on Thursday, April 28, 2022 at 06:00 AM. Here''s what investors need to know about the announcement. Earnings NovoCure beat estimated earnings by 77.78%, reporting an EPS of $-0.04 versus an … Full story available on Benzinga.com
NovoCure GAAP EPS of -$0.04 beats by $0.15, revenue of $137.55M beats by $3.26M 2022/04/28 11:06:38 Seeking Alpha
NovoCure press release (NVCR): Q1 GAAP EPS of -$0.04 beats by $0.15.Revenue of $137.55M (+2.1% Y/Y) beats by $3.26M.Gross margin for the quarter was 80%. As of March 31, 2022,…
Novocure to Report Third Quarter 2021 Financial Results 2021/10/04 11:30:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure announced that it will report financial results for the third quarter 2021 on Thursday, October 28, 2021.
Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China 2021/10/04 11:30:00 Intrado Digital Media
Final data collection is expected in the first half of 2022
Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China 2021/10/04 11:30:00 Business Wire
ST. HELIER, Jersey & SHANGHAI--(BUSINESS WIRE)-- #GastricCancer--Novocure and Zai Lab announced that the last patient has been enrolled in a phase 2 pilot trial of TTFields plus chemotherapy in gastric cancer.
Novocure To Test Its Tumor Treating Fields With Roche''s Tecentriq In Pancreatic Cancer 2021/09/14 12:34:37 Benzinga
Novocure Ltd (NASDAQ: NVCR ) has entered into a clinical trial collaboration agreement with Roche Holdings AG (OTC: RHHBY ) to develop Tumor Treating Fields (TTFields) together with Roche''s atezolizumab in metastatic pancreatic ductal adenocarcinoma (mPDAC). The phase 2 study was designed to test the safety and efficacy of TTFields together with atezolizumab, gemcitabine, and nab-paclitaxel as Full story available on Benzinga.com